GLP-1 pharmaceutical compositions
View Patent ↗The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.
1. A pharmaceutical composition comprising an analog according to the formula:
[Aib 8,35 , Arg 26,34 , Phe 31 ]hGLP-1(7-36)NH 2
together with zinc and a pharmaceutically acceptable carrier or diluent.
2. A composition according to claim 1 , wherein said zinc is present in a concentration from 0.0005 mg/mL to 50 mg/mL.
3. A pharmaceutical composition according to claim 1 or 2 wherein said composition forms a precipitate after subcutaneous administration to a subject.
4. A composition according to claims 1 or 2 , wherein the analog is present in an aqueous solution with a pH lower than 7.
5. A composition according to claims 1 or 2 , wherein the analog is present in a concentration of about 0.001-500 mg/mL.
6. A composition according to claim 2 , wherein said zinc is present in a concentration from 0.01 mg/mL to 0.50 mg/mL.
7. A composition according to claim 4 , wherein the analog is present in an aqueous solution with a pH lower than 5.
8. A composition according to claim 5 , wherein the analog is present in a concentration of about 0.1-10 mg/mL.
9. A composition according to any one of claims 1 , 2 , 6 , 7 , and 8 , wherein said diluent comprises a pharmaceutically acceptable aqueous solution.